The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with advanced or metastatic solid tumors without standard treatment options to participate in a research study. This study will evaluate the investigational drug XB002 alone or in combination with nivolumab or bevacizumab. XB002 is considered an investigational drug for use in this study because it has not been approved by the FDA; its safety and efficacy have not been established. XB002 is used to treat cancer.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed or Refractory Multiple Myeloma. The purpose of this study is to see how the study medication in combination with daratumumab and pomalidomide (Tal-DP) or the study medication and daratumumab (Tal-D) compares to daratumumab, pomalidomide, and dexamethasone (DPd) in treating patients with multiple myeloma, who have not responded to previous treatment. There are three treatment arms in this study. You will randomly, or by chance, be put into one of the treatment arms:

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have mantle cell lymphoma. The purpose of this study is to test the efficacy and safety of an investigational treatment called pirtobrutinib. Pirtobrutinib is an investigational drug that may treat certain cancers like leukemia and lymphomas, including the type of cancer you were diagnosed with, mantle cell lymphoma (MCL). These cancers are dependent on or “addicted to” a protein called “BTK”.

The University of Virginia Center for Diabetes Technology & the University of Colorado Anschutz Medical Campus seeks adults between the ages of 30-80 who have Type 2 Diabetes to participate in a clinical study. The purpose of this study is to find out if people who are newly diagnosed with Type 2 Diabetes respond better to regular routine care or routine care paired with a lifestyle intervention that focuses on reducing how much blood glucose goes up after eating, by avoiding certain foods and increasing routine physical activity.

The University of Virginia is participating a clinical research study for adults ages 18 and over, who have Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. As part of this study, you will either be treated with continued regular standard of care therapy or with an investigational medication for 5 years. Both medications are a pill.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who relapsed or refractory lymphomas, large granular lymphocytic leukemia, or solid tumors. There are two parts to this study – Phase 1a and Phase 1b. You can participate in only one of the phases. The study doctor will discuss which treatment groups you may be suitable for. The purpose of the Phase 1a study is to determine the maximum dose of the study drug KT-333 that can be given that is well tolerated by patients with relapsed or refractory (R/R) lymphoma, LGL-L and solid tumors.

The UVA Nephrology Clinical Research Center seeks healthy adults aged 18 and up to participate in a research study. The aim of the study is to see if a blood test can help establish a new method to detect and characterize biomarkers for subjects with chronic kidney disease with or without heart disease.

The study involves a one-time visit to the clinic, which will last approximately 30 minutes. The subject will provide one blood sample. Free parking will be provided.

The UVA Cancer Center is enrolling patients with stage III melanoma that has spread to one lymph node in the armpit, hip, or groin to a clinical research study. Patients with this type of cancer usually undergo surgery to remove all the lymph nodes in the affected area. This type of surgery is known as a TLND (therapeutic lymph node dissection).

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with advanced solid tumors to participate in a research study. The study will test the safety and tolerability of an investigational drug called XmAb662 alone or XmAb662 given in combination with pembrolizumab. XmAb662 is considered an investigational drug for use in this study because it has not been approved by the FDA. The purpose of this study is to determine the effect, good and/or bad, the investigational drug has on your cancer by testing different dose levels.

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been diagnosed with relapsed or refractory neuroblastoma. This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to treatment (refractory).